Placental site trophoblastic tumors are a group of benign and malignant neoplasms that develop from trophoblastic cells, which are part of the placenta. These tumors can range from molar pregnancy, which is benign, to choriocarcinoma, which is malignant. Trophoblastic tumors arise from abnormal processes that can occur during pregnancy and can have serious consequences for both mother and fetus. In most cases, early diagnosis and appropriate treatment can lead to positive outcomes.
History of the disease and interesting historical facts
The history of trophoblastic tumors research dates back to the early 20th century, when data on molar pregnancy and choriocarcinomas began to be collected and analyzed. In the 1930s, American pathologist D. M. Bender described various forms of trophoblastic tumors, which contributed to a deeper understanding of their morphology and clinical features. In the 1940s, the concept was developed that trophoblastic tumors can be classified as benign and malignant. Interestingly, trophoblastic tumors became the focus of scientific attention in the 20th century, as their study contributed to significant progress in the field of oncology and assisted reproductive technologies.
Epidemiology
According to epidemiological studies, trophoblastic tumors occur at a frequency of 1 in 1000–1500 pregnancies. Studies show that molar pregnancy is the most common form, accounting for about 80% of all cases, while choriocarcinoma is observed in only 1 in 30,000 pregnancies. It is important to note that the prevalence of trophoblastic tumors may vary depending on the region, race, and age of the women. For example, in some communities with high rates of chimeric pregnancy (such as among women in Asia), the likelihood of trophoblastic tumors may be significantly higher.
Genetic predisposition to this disease
Genetic predisposition to trophoblastic tumors, especially molar pregnancy, may be related to abnormalities in gamete ploidy. In most cases, molar pregnancy is characterized by the deletion of one or both chromosomes from the fertilized egg, resulting in the formation of abnormal cells. Studies have shown that mutations in certain genes, such as TP53 and KRAS, may contribute to the development of choriocarcinoma. Because these tumors develop from trophoblastic cells, it is important to consider both chromosomal and genetic changes that may contribute to their formation.
Risk factors for the development of this disease
The risk of developing trophoblastic tumors may be increased by a number of factors. It is important to highlight the following groups of risk factors:
- Physical factors: previous pregnancy abnormalities such as number of previous stillbirths and history of molar pregnancies.
- Chemical factors: Exposure of the body to certain chemicals, including pesticides and certain medications, can interfere with the normal development of the trophoblast.
- General predisposition: the woman's age, with women over 35 years of age having a higher risk of developing a molar pregnancy.
- Genetic factors: A family history of trophoblastic tumors also increases the risk of their development in offspring.
Diagnosis of this disease
To diagnose trophoblastic tumors, it is necessary to consider clinical symptoms and the results of several diagnostic studies. The main symptoms may include abnormal vaginal bleeding, an enlarged uterus, the presence of tumor-like formations, and increased production of human chorionic gonadotropin (hCG) in the blood.
Laboratory tests include:
- Determination of the hCG level in the blood serum, which allows assessing the activity of the tumor.
- Histological examination of tissue samples obtained during biopsy.
Radiological examinations in the form of ultrasound and CT allow visualization of tumors in the uterus and other organs. It is important to conduct a differential diagnosis with other gynecological diseases, such as uterine fibroids or ovarian cancer.
Treatment
Treatment of trophoblastic tumors depends on their type and stage. In general, the following approaches can be distinguished:
- General treatment: includes observation and regular monitoring of hCG levels.
- Pharmacological treatment: used in malignant forms and may include chemotherapy (eg, using methotrexate).
- Surgical treatment: may be aimed at removing the tumor or the uterus if there is no desire to preserve the fetus.
- Other treatments: In some cases, targeted therapy and immunotherapy may be used.
List of medications used to treat this disease
Among the drugs used to treat trophoblastic tumors are:
- Methotrexate
- Cisplatin
- etoposide
- Doxorubicin
- Foliar acid
Disease monitoring
Monitoring of trophoblastic tumors includes regular examinations and monitoring of hCG levels. The prognosis depends on the type of tumor and the stage at the time of treatment. Possible complications may include recurrence of the disease, menstrual irregularities, and problems with reproductive health in the future.
Age-related features of the disease
Trophoblastic tumors can occur in women of different age groups, but a high incidence is observed in young and middle age. In women over 35 years of age, the risk of molar pregnancy increases, which requires more careful monitoring and screening.
Questions and Answers
- What are the main symptoms of trophoblastic tumor? The main symptoms include abnormal vaginal bleeding, an enlarged uterus, and elevated hCG levels in the blood.
- What risk factors contribute to the development of trophoblastic tumors? Risk factors include previous molar pregnancies, maternal age, and chemical exposure.
- How are trophoblastic tumors diagnosed? Diagnosis is based on hCG levels, ultrasound and histopathological analysis.
- How is trophoblastic tumor treated? Treatment may include surgery and chemotherapy depending on the type of tumor.
- What is the prognosis for women with trophoblastic tumors? The prognosis depends on the stage of the disease, but with early detection and treatment, most women have favorable outcomes.
